Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Tokushukai Committed to Settling Prices by End of September
August 11, 2008
- R&D NEWS IN BRIEF
August 11, 2008
- MSNW Supports Rational Drug Pricing
August 11, 2008
- GENERICS NEWS IN BRIEF
August 11, 2008
- JPMA Members Improving Distribution Business Practices: Mr Negi
August 11, 2008
- JRCS Considers Joint Purchase of Generics
August 11, 2008
- Price Settlement Rate Remains at 18% as of June 30: NPhA
August 11, 2008
- Gov't Plans to Create 20 "Super Tokku"
August 11, 2008
- Avapro Holds Top Position 2 Months in a Row: Rep Track Survey
August 11, 2008
- No Additional Safety Measures Needed for Zetia, Comtan: EPPV
August 4, 2008
- Patients Should Speak out to Improve the Quality of Healthcare
August 4, 2008
- Korosho Calls For Precautions on Use of Risedronate
August 4, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 4, 2008
- Roche Acquires Mirus to Advance RNAi Delivery Research
August 4, 2008
- Negative Primary Balance of \3.9 Tril. Projected in FY2011
August 4, 2008
- Erbitux to Enhance Merck Serono's Presence in Japan
August 4, 2008
- Roche to Acquire Arius for C$191 Million
August 4, 2008
- 61.4% of People Favor Use of Consumption Tax for Social Security Services
August 4, 2008
- Roche to Completely Acquire Genentech
August 4, 2008
- Nippon Zoki Out-licenses NZ-419 to Hyundai Pharm. of South Korea
August 4, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…